8ème congrès de la Société Francophone de Thérapie Cellulaire et Génique Paris, 21-23 Juin 2009

Cher(e)s Collègues,

La Société Francophone de Thérapie Cellulaire et Génique (SFTCG) est heureuse de vous annoncer que son prochain congrès annuel se tiendra du 21 au 23 juin prochain à Paris à la .faculté de médecine Pierre et Marie Curie, site pitié salpêtrière (105 bld de l'hôpital 75013 Paris.

Comme vous le savez, notre société a pour but de promouvoir la recherche fondamentale et clinique en thérapie cellulaire et génique. Ce congrès réunira donc la communauté scientifique académique et industrielle francophone intéressée au développement des Biothérapies Cellulaires et Géniques, qui représente un champ thérapeutique en plein essor. Comme pour les colloques précédents, l'objectif principal de cette réunion est d'offrir aux jeunes chercheurs et aux doctorants la possibilité de rencontrer les leaders dans leur domaine de recherche, mais aussi de leur donner l'occasion de présenter leurs propres travaux, à partir de résumés sélectionnés. Pour encourager leur participation, les jeunes bénéficieront de tarifs préférentiels, et des prix seront attribués aux meilleures présentations orales et affichées.

Agrandir le plan

Télécharger le progamme en anglais

liste des participants congres 2009

Inscription statutaire congrès 2009
Inscription non statutaire congrès 2009
Inscription industriel congrès 2009

Soumettre un résumé

SUNDAY JUNE 21
11h30	Opening ceremony
11h45- 12h30	Special lecture (1) : Rudolf JAENISCH The Whitehead Institute and MIT, Cambridge, MA, USA "Stem cells, pluripotency and nuclear reprogramming"
12h30- 14h00	Lunch
14h00-16h00	Cell therapy session Michel PUCÉAT INSERM Avenir Program, Campus Genopole 1, Evry, France "Early primate multipotent cardiovascular progenitors derived from pluripotent stem cells safely engraft in postmyocardial infarcted primate: A proof of principle in regenerative medicine" Emmanuelle CHARAFE-JAUFFRET Biopathologie, Centre de Recherche en Cancérologie, Marseille, France ”Tumor stem cells mediate the metastatic phenotype in inflammatory breast cancer” Selected oral presentations Rima Haddad INSERM U935, University Paris 11, Villejuif, France ”Induction of hematopoiesis in human induced pluripotent stem cells in comparison with human embryonic stem cells” Thomas Touboul INSERM U972 ; Université Paris-Sud ; Hôpital Kremlin-Bicêtre, France ”Generation of hepatocytes from human embryonic stem cells: in vitro and in vivo functional studies” Yamina Hamel CNRS UMR 7211 & Université Pierre et Marie Curie-Paris6, Paris, France “Preparation of human alloantigen-specific natural regulatory T-cells“
16h-16h30	Coffee break
16h30-18h30	Vectorology session Nicolas MERMOD University of Lausanne, Lausanne, Switzerland "Characterization of Insulators and Barrier Elements for Gene Therapy" Axel RETHWILM Institut für Virologie und Immunbiologie, Würzburg, Germany. "Development of Foamy Virus Vectors" Selected oral presentations Odile Cohen-Haguenauer LBPA/ CLINIGENE, Ecole Normale Superieure (ENSC), Cachan, France “Insulated retroviral vectors towards safe and efficient genetic modification of stem cells“ Cecilia Frecha Inserm U758, Ecole Normale Supérieure de Lyon, Université Lyon 1, France “Measles virus gp pseudotyped LVs allow efficient transduction of quiescent B-cells by using a highway to the nucleus. “ Anthony Delalande UPR 4301 CNRS, Université d'Orléans, Inserm U930, Tours, France “Ultrasound-assisted microbubbles mediates long term gene expression in Achilles tendon“
18h30-19h15	Special lecture (2): David KLATZMANN Immunology-Immunopathology-Immunotherapy (I3), UPMC, CNRS, INSERM, Paris, France "Of Treg and therapy"
19h15- 21h00	Poster session (viewing) & welcome reception

MONDAY JUNE 22
8h30-11h00	Vaccinology-Immunotherapy-Infectious diseases Mary COLLINS Infection and Immunity, University College London, London,UK. "Lentiviral vectors as vaccines" Claude LECLERC Immune Regulation and Vaccinology, Institut Pasteur, Inserm U833, Paris, France "Treatment of large established tumors by combined immunotherapy targeting adaptive and regulatory responses" François-Loïc COSSET Université de Lyon 1, Inserm U758, ENS de Lyon, Lyon, France "Engineering and vectorization of virus-like particles (VLPs) as novel vaccines to combat acute and chronic infectious diseases" Selected oral presentations Florence Boisgérault INSERM U951, GENETHON, Evry, France “Administration of miRNA142.3p-regulated rAAV2/1 vectors in skeletal muscle reduces the initial anti-transgene immune response” Céline Terrada UPMC, CNRS UMR7211, INSERM U959, CERVI, Paris, France “Cellular therapy using regulatory T cells in uveitis “ Laetitia Mercey CNRS UMR 7211 & Université Pierre et Marie Curie-Paris6, Paris, France “Towards HIV gene therapy in humanized mice “
11h00-11h30	Coffee Break
11h30-13h30	Session on clinical trials Robin R. ALI Institute of Ophtalmology, University College London, London, UK “Gene therapy for inherited retinal degeneration: from mouse to man” Gillian BUTLER-BROWNE UMR S 974, Inserm, UPMC, Institut de Myologie ; UMR 7215 CNRS, Paris, France “Oculopharyngeal muscular dystrophy (OPMD): a good candidate for myoblast transplantation” Selected oral presentations Françoise Schmitt INSERM U948, Biothérapies Hépatiques, EA4274, Nantes, France “Long-term and complete correction of hyperbilirubinemia in immunocompetent adult gunn rats by in vivo lentiviral gene delivery” Matthias Titeux INSERM, U563, Université Toulouse III Paul Sabatier, Toulouse, France “Exon skipping gene therapy for Dystrophic Epidermolysis Bullosa “ Maciej Malecki Centre of Oncology, 02-781 Warsaw, 5 Roentgen str., Poland “Antiangiogenic gene therapy: an application of plasmid vector encoding soluble FLT-1 receptor for locally advanced vulvar cancer “
13h30- 15h00	POSTER SESSION (presentations) & LUNCH
15h00-16h00	General Assembly of SFTCG THERMO FISHER SCIENTIFIC award
16h00-18h00	Session on new gene therapy approaches Florence APPARAILLY Inserm U844, Université Montpellier 1, CHU Lapeyronie, Montpellier, France "In vivo RNAi for successful design of alternative therapies in autoimmunity" Annemieke AARTSMA-RUS Leiden University Medical Center, Leiden, The Netherlands "Antisense-mediated exon skipping for Duchenne Muscular Dystrophy" Selected oral presentations Trevor N. Collingwood Sigma Aldrich R&D Saint Louis US “Targeted Genome Editing in Mammalian Cells Using Engineered Zinc Finger Nucleases” Monique Bolotin-Fukuhara Institut de Génétique et Microbiologie, UMR 8621, Orsay, France “Upstream of gene therapy : yeast as a tool to select correcting genes“ William Lostal Centre of Oncology, 02-781 Warsaw, 5 Roentgen str., Poland “Efficient in vivo dysferlin expression by dual AAV vectors reconstruction“ Johannes Fruehauf Cequent Pharmaceuticals Inc., Boston, MA, USA “Development of a therapeutic RNAi delivery system using nonpathogenic bacteria expressing inv and hly: transkingdom RNA interference (tkRNAi) “

TUESDAY JUNE 23
	Special thematic session: “BIOSAFETY IN CELL AND GENE THERAPY”
8h30-10h30	Retroviral vectors and insertional mutagenesis Alain FISCHER Inserm U768, Hôpital Necker, Université Paris Descartes, Paris, France “Gene therapy of SCID: a 10-year survey“ Christopher BAUM Experimental hematology, Hannover Medical School, Hannover, Germany “Retroviral vectors and insertional mutagenesis” Emmanuel PAYEN CEA/IMETI – Inserm U962 - Fontenay aux roses, France. “Clinical benefit with clonal dominance after lentiviral gene therapy for severe human beta thalassemia.” Jean-Christophe PAGÈS Inserm U966, Université de Tours, Tours, France. “Which model to measure vector-induced integration risk? A regulatory perspective.”
	Round table
10h30-11h00	Coffee Break
11H00-13h00	Chromosomal instability and mesenchymal stem cells Luc SENSEBÉ Etablissement français du sang (EFS), Tours, France "Clinical-grade Mesenchymal Stem Cells: aneuploidy is not transformation" Sophie LUCAS AFSSAPS (French Health Products Agency), Saint Denis, France “Chromosomal instability and mesenchymal stem cells” Jean- Paul RENARD UMR Biologie du développement et reproduction, INRA, Jouy en Josas, France “Reprogramming somatic nuclei into embryonic nuclei through nuclear transfer and the stem cell potential of the derived cell lines “
	Round table
13H00-14h30	LUNCH
14H00-16h00	Use of viral particles in gene therapy and vaccination: Immunological consequences Jim WILSON University of Pennsylvania, Philadelphia, USA "Immune reactions to Adenovirus and AAV (natural infection and viral vectors)" Philippe MOULLIER INSERM UMR 649, CHU de Nantes, Université de Nantes, Nantes, France “Mode of delivery and cell tropism vs immunotoxicity of recombinant AAV in nonhuman primate“ Isabelle RICHARD Généthon, Evry, France "AAV-mediated gene transfer in limb-girdle muscular dystrophies: complex strategies and biosafety issues"
	Round table
	Concluding remarks about biosafety in cell and gene therapy Jean-Hugues TROUVIN, AGEPS, Paris, France
16H00-16h30	Best oral presentation and best poster awards
	Closure